PMID-19719703 – Exenatide Efficacy and Safety Systematic Review
Bentley-Lewis R, Aguilar D, Riddle MC, et al. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26(9):837-846.
Quick Reference
| Property | Value |
|---|---|
| PMID | 19719703 |
| DOI | 10.1111/j.1464-5491.2009.02790.x |
| Year | 2009 |
| Journal | Diabetic Medicine |
| Study Type | Systematic Review |
| Evidence Level | I |
| Sample | Multiple RCTs pooled |
| Peptide(s) Studied | Exenatide |
Key Findings
- In placebo-controlled trials, exenatide 10 mcg BID improved HbA1c by approximately 1.0% over 30 weeks
- Weight loss of 1.0-2.5 kg observed across trials (advantage over insulin comparators which caused weight gain)
- In active-comparator trials, exenatide produced HbA1c reductions similar to adding another oral agent or initiating insulin
- Most common adverse event was nausea (dose-dependent, transient, generally mild-to-moderate)
- Low rates of hypoglycemia when used without sulfonylureas
- No significant effects on lipid profiles beyond those attributable to weight loss
Study Design
Systematic review of published RCTs evaluating exenatide (both twice-daily immediate-release and once-weekly extended-release formulations) in patients with type 2 diabetes. Included placebo-controlled and active-comparator trials across various background therapies.
Limitations
- Limited to published trials available at the time (pre-EXSCEL, pre-DURATION long-term data)
- Heterogeneity in background therapy and patient populations across trials
- Most trials were 24-30 weeks in duration, limiting long-term safety conclusions
- Industry sponsorship of most included trials
Clinical Relevance
This systematic review established exenatide's profile as a clinically effective GLP-1 RA with the unique advantage of weight loss compared to insulin or sulfonylurea alternatives. As the first approved GLP-1 RA, exenatide's efficacy and safety data formed the foundation for the entire class. The weight-neutral-to-weight-loss profile became a defining feature that distinguished GLP-1 RAs from other T2D therapies.
Related
#research #systematic-review #evidence-level-I #metabolic #exenatide